Business
Hikma launches 100th injectable medicine in US
Hikma launches 100th injectable medicine in US.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 6420X Hikma Pharmaceuticals Plc 01 May 2019 \n\nLondon, 1 May 2019 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) the multinational pharmaceutical company, today launched its 100th injectable medicine in the United States with the introduction of Vancomycin Hydrochloride for Injection, USP, 5g, 10g and 750mg, through its US affiliate, Hikma Pharmaceuticals USA Inc.1\n\"Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it's another important addition to our growing US portfolio,\" said Dan Motto, Executive Vice President, Commercial and Development, Injectables. \"This launch marks a great milestone - Hikma's 100th injectable medicine in the US - and it demonstrates our commitment to providing doctors and hospitals with a broad range of high-quality medicines needed to treat the current and future needs of patients.\"\nHikma's Vancomycin Hydrochloride for Injection, USP is indicated for: \n· the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam- resistant) staphylococci; \n· patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by Vancomycin-susceptible organisms that are resistant to other antimicrobial drugs; \n· initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly;\n· the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures;\n \nand has been:\n \n· reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis. For endocarditis caused by...